Synchron, an endovascular brain-computer interfacing (BCI) company announced the first American human implant. This is the first US procedure to use a BCI endovascular approach, which does not require open brain surgery.
“Our technology is designed for millions of people who are unable to control digital devices with their hands. Synchron stated that they are thrilled to offer a scalable BCI solution to many people.
Under the supervision of Shahram Majidi (MD), clinical investigator and assistant professor of neurosurgery at Mount Sinai, the procedure was carried out at Mount Sinai West in New York. The procedure was done in the angiography area using a minimally invasive, endovascular approach.
This study will assess the safety and effectiveness of the device in patients with severe paralysis. It will allow the patient to use digital devices hands-free. The study will use brain data to control digital devices, and increase functional independence.
Shahram Majidi said, “This is an exciting milestone in this field because it has implications and great potential.” “The procedure was successful and the patient was able go home within 48 hours.
“The US’s first BCI-endocrine implant is a significant clinical milestone that opens new possibilities for patients suffering from paralysis,” stated Tom Oxley, MD and CEO of Synchron. “Our technology is for millions who have lost the ability of their hands to control digital devices. We are thrilled to offer a scalable BCI solution which has the potential for many lives to be changed.
The minimally invasive endovascular procedure allows the stentrod to be inserted into the motor cortex via the jugular. It wirelessly transmits motion intent to the motor cortex using a proprietary digital code. This allows severely paralyzed people to use their personal devices without having to touch them. These tests will evaluate the ability to perform everyday tasks like texting, emailing and shopping online.
